Product NDC: | 49708-419 |
Proprietary Name: | Synalgos |
Non Proprietary Name: | Aspirin, Caffeine, and Dihydrocodeine Bitartrate Capsules |
Active Ingredient(s): | 356.4; 30; 16 mg/1; mg/1; mg/1 & nbsp; Aspirin, Caffeine, and Dihydrocodeine Bitartrate Capsules |
Administration Route(s): | ORAL |
Dosage Form(s): | CAPSULE |
Coding System: | National Drug Codes(NDC) |
Product NDC: | 49708-419 |
Labeler Name: | Caraco Pharma Inc. |
Product Type: | HUMAN PRESCRIPTION DRUG |
FDA Application Number: | NDA011483 |
Marketing Category: | NDA |
Start Marketing Date: | 20081230 |
Package NDC: | 49708-419-88 |
Package Description: | 100 CAPSULE in 1 BOTTLE (49708-419-88) |
NDC Code | 49708-419-88 |
Proprietary Name | Synalgos |
Package Description | 100 CAPSULE in 1 BOTTLE (49708-419-88) |
Product NDC | 49708-419 |
Product Type Name | HUMAN PRESCRIPTION DRUG |
Non Proprietary Name | Aspirin, Caffeine, and Dihydrocodeine Bitartrate Capsules |
Dosage Form Name | CAPSULE |
Route Name | ORAL |
Start Marketing Date | 20081230 |
Marketing Category Name | NDA |
Labeler Name | Caraco Pharma Inc. |
Substance Name | ASPIRIN; CAFFEINE; DIHYDROCODEINE BITARTRATE |
Strength Number | 356.4; 30; 16 |
Strength Unit | mg/1; mg/1; mg/1 |
Pharmaceutical Classes | Cyclooxygenase Inhibitors [MoA],Decreased Prostaglandin Production [PE],Nonsteroidal Anti-inflammatory Compounds [Chemical/Ingredient],Nonsteroidal Anti-inflammatory Drug [EPC],Central Nervous System Stimulant [EPC],Central Nervous System Stimulation [PE],Methylxanthine [EPC],Xanthines [Chemical/Ingredient],Full Opioid Agonists [MoA],Opioid Agonist [EPC] |